Jitsubo CO., LTD. announced  the signing of an exclusive manufacturing license agreement with Novo Nordisk A/S（2880 Bagsvaerd, Denmark, hereinafter “Novo Nordisk”）for Novo Nordisk to use and have manufacturing rights to Jitsubo’s proprietary peptide manufacturing technology, Molecular Hiving^TM, for synthesis of peptides in the field of obesity, diabetes, and the related therapeutic areas.

News Release PDF